A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Westmead, Australia, 2145
- The Children's Hospital at Westmead
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- The Royal Children's Hospital, Melbourne
-
-
-
-
-
Wien, Austria
- AKH Wien (Paediatrics)
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N3Z5
- McMaster Children's Hospital
-
-
-
-
-
Brno, Czech Republic, 625 00
- Fakultni nemocnice Brno
-
Ostrava, Czech Republic, 708 52
- Fakultni Nemocnice Ostrava
-
Praha 5, Czech Republic, 150 06
- Fakultni nemocnice Motole
-
-
-
-
-
Le Kremlin-Bicentre, France, 94275
- C.R.T.H. Hopital de Bicentre (Hemophilie)
-
Lyon, France, 69437
- Hospital Edouard Herriot
-
Marseille, France, 13385
- Hopital d'Enfants la Timone
-
-
-
-
-
Duisburg/Altstadt, Germany, 47051
- CRC Coagulation Research Center GmbH
-
Düsseldorf, Germany, 40225
- Universitätsklinikum Düsseldorf
-
-
-
-
-
Tel Hashomer, Israel, 52621
- Sheba medical center
-
-
-
-
-
Firenze, Italy, 50134
- Aou Careggi
-
Milano, Italy, 20122
- IRCCS Ospendale Maggiore (Centro emofilia e Trombosi)
-
-
-
-
-
Kirov, Russian Federation, 610027
- FGU "Kirov Research Institute of Haemotology and Blood Trans)
-
-
-
-
-
Madrid, Spain, 28046
- H.U. La Paz
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subjects, younger than 12 years old.
- Severe hemophilia B (Factor IX [FIX] activity of ≤ 2%).
- Body weight ≥ 10 kg.
- Subjects who have received FIX products (plasma-derived and/or recombinant FIX) for > 150 exposure days (EDs) (6 to < 12 years), and > 50 EDs (< 6 years).
- No history of FIX inhibitor formation, no detectable inhibitors at Screening and no family history of inhibitors against FIX.
- Written informed consent for study participation.
Exclusion Criteria:
- Known hypersensitivity to any FIX product or hamster protein.
- Known congenital or acquired coagulation disorder other than congenital FIX deficiency.
- Kidney or liver disease.
- Recent life-threatening bleeding episode.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: rIX-FP
Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.
|
Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incremental Recovery Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product
Time Frame: 30 minutes after infusion
|
Incremental recovery (IU/dL/IU/kg) is defined as the FIX activity (IU/dL) obtained 30 minutes following infusion, per dose of (IU/kg) infusion.
FIX activity was measured at a central laboratory using validated one-stage clotting method.
Recovery values were baseline-corrected for pre-infusion plasma FIX activity.
Incremental recovery was measured following a single intravenous dose of 50 IU/kg rIX-FP on Day 1. Analysis of previous FIX product was conducted at the beginning of the study in a subset of subjects who had no historical pharmacokinetic (PK) data of their previous FIX product.
For the PK assessment, the previous FIX product was administered by IV infusion after approximately 4 days following the last FIX treatment, prior to any dosing of rIX-FP.
The formal PK population consisted of subjects who received at least 1 dose of rIX-FP for PK assessment and for whom a sufficient number of analyzable PK samples had been obtained to permit the evaluation of the PK profile of rIX-FP.
|
30 minutes after infusion
|
|
Half-life (t1/2) Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product
Time Frame: Pre-dose, 30 minutes, 3, 24, 48, 72 120, 168, 240 and 336 hours post-dose
|
FIX activity was measured at a central laboratory using validated one-stage clotting method.
FIX levels were not corrected for baseline values.
|
Pre-dose, 30 minutes, 3, 24, 48, 72 120, 168, 240 and 336 hours post-dose
|
|
Area Under the Concentration Versus Time Curve From Time Point Zero to the Last Sample With Quantifiable Drug Concentration (AUClast)
Time Frame: Pre-dose, 30 minutes, 3, 24, 48, 72 120, 168, 240 and 336 hours post-dose
|
AUClast following a single intravenous dose of 50 IU/kg rIX-FP or previous FIX product. FIX activity was measured at a central laboratory using validated one-stage clotting method. FIX levels were not corrected for baseline values. |
Pre-dose, 30 minutes, 3, 24, 48, 72 120, 168, 240 and 336 hours post-dose
|
|
Clearance for FIX Activity Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product
Time Frame: Pre-dose, 30 minutes, 3, 24, 48, 72 120, 168, 240 and 336 hours post-dose
|
FIX activity was measured at a central laboratory using validated one-stage clotting method.
FIX levels were not corrected for baseline values.
Clearance is normalized for body weight.
|
Pre-dose, 30 minutes, 3, 24, 48, 72 120, 168, 240 and 336 hours post-dose
|
|
Number of Subjects Developing Inhibitors to Factor IX (FIX)
Time Frame: 12 months
|
Inhibitor formation was defined as any inhibitor (≥0.6 BU [Bethesda Units]/mL) identified and confirmed by retesting.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects With Treatment-related Adverse Events
Time Frame: 12 months
|
12 months
|
|
|
Number of Subjects Developing Antibodies Against rIX-FP
Time Frame: 12 months
|
Antibodies to rIX-FP were measured using a direct-binding enzyme-linked immunosorbent assay (ELISA).
|
12 months
|
|
Number of Bleeding Episodes Requiring One, Two or More Than Two Infusions of rIX-FP to Achieve Hemostasis
Time Frame: Approximately 12 months
|
For each bleeding episode that required treatment, the number of episodes that required one, two or more than two infusions of rIX-FP to achieve hemostasis
|
Approximately 12 months
|
|
Consumption of rIX-FP During Routine Prophylaxis
Time Frame: 12 months
|
Consumption of rIX-FP during routine prophylaxis is expressed as the total prophylaxis dose per month.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CSL654_3002
- 2011-006032-23 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.